Also, among the trans women who underwent estrogen therapy through Kaiser Permanente, adjusted odds of VTE were 2.7 times higher than reference men and 1.5 times higher than reference women. An increase in stroke rate was also more apparent when the analysis focused only on those with confirmed hormone therapy.
“The present study demonstrated that cross-sex estrogen is a risk factor for VTE and probably ischemic stroke among transfeminine persons,” wrote lead author Darios Getahun, MD, PhD, and colleagues. “We also observed that patterns of VTE and ischemic stroke incidence among transfeminine persons receiving hormone therapy were different from those reported in cisgender women receiving hormone replacement therapy. If confirmed, these results may indicate the need for increasing vigilance in identifying long-term vascular side effects of estrogen therapy in transgender patients.”
Getahun et al. found rates of myocardial infarction were greater among transwomen than cisgender women but similar to the incidence observed in men. They didn’t find evidence of any increased risk for transmasculine participants.
The authors noted the primary limitation of their study is it couldn’t account for hormone therapy that people may have received from other sources. This highlights the challenge of quantifying patients’ complete history of hormone use, they said.
“In the meantime, it is critical to keep in mind that the risk for (acute cardiovascular events) in this population must be weighed against the benefits of treatment,” Getahun and coauthors wrote.
Source : https://www.cardiovascularbusiness.com/topics/vascular-endovascular/hormone-treatment-trans-women-boost-vte-risk245